var data={"title":"Metreleptin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Metreleptin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/719492?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=metreleptin-drug-information\" class=\"drug drug_general\">see &quot;Metreleptin: Drug information&quot;</a> and <a href=\"topic.htm?path=metreleptin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Metreleptin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147898\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Antibody formation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Anti-metreleptin antibodies with neutralizing activity have been identified in patients treated with metreleptin. The consequences of these neutralizing antibodies are not well characterized but could include inhibition of endogenous leptin action and/or loss of metreleptin efficacy. Severe infection and/or worsening metabolic control have been reported. Test for anti-metreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs suspicious for loss of metreleptin efficacy during treatment. Contact Aegerion Pharmaceuticals, Inc. at 1-866-216-1526 for neutralizing antibody testing of clinical samples.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Lymphomas: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy, both treated and not treated with metreleptin. Carefully consider the benefits and risks of treatment with metreleptin in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">REMS program: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Because of these risks associated with the development of anti-metreleptin antibodies that neutralize endogenous leptin and/or metreleptin and the risk for lymphoma, metreleptin is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the Myalept REMS Program.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673744\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Myalept</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046428\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Leptin Analog</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046431\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=metreleptin-drug-information\" class=\"drug drug_general\">see &quot;Metreleptin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Lipodystrophy:</b> Infants, Children, and Adolescents: The manufacturer&rsquo;s labeling describes use in infants; however, in trials, the minimal inclusion age was 6 months and the youngest subjects reported in trials and case series were at least 1 year of age (Diker Cohen 2015). <b>Note:</b> Increase or decrease dose based on clinical response (eg, inadequate metabolic control) or other considerations (eg, tolerability issues, excessive weight loss).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline weight &le;40 kg, male and female patients: SubQ: Initial: 0.06 mg/kg/dose once daily; adjust dose (increase or decrease) in 0.02 mg/kg increments based on response or adverse effects. Maximum daily dose: 0.13 mg/kg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline weight &gt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female patients: SubQ: Initial: 5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Male patients: SubQ: Initial: 2.5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinuation: When discontinuing therapy in patients with risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia), taper the dose over a 1-week period and monitor triglyceride levels; consider initiating or adjusting the dose of lipid-lowering medications as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Lipodystrophy: Note:</b> Increase or decrease dose based on clinical response (eg, inadequate metabolic control) or other considerations (eg, tolerability issues, excessive weight loss).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline weight &le;40 kg, male and female patients: SubQ: Initial: 0.06 mg/kg/dose once daily; adjust dose (increase or decrease) in 0.02 mg/kg increments based on response or adverse effects. Maximum daily dose: 0.13 mg/kg/ <b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Baseline weight &gt;40 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Female patients: SubQ: Initial: 5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Male patients: SubQ: Initial: 2.5 mg once daily, adjust dose (increase or decrease) in 1.25 to 2.5 mg increments based on response or adverse effects; maximum daily dose: 10 mg/<b>day</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Discontinuation: When discontinuing therapy in patients with risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia), taper the dose over a 1-week period and monitor triglyceride levels; consider initiating or adjusting the dose of lipid-lowering medications as needed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24673745\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Myalept: 11.3 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147902\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24170123\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125390s010lbl.pdf#page=14&amp;token=hU6dSXjOFpeSwyW6YoF+blZpJr1wkFeNJ8fte7k00HOWsjmuSbxVqOKBr6jU3YWV3MKSdSjDgPrG2y2bzcMi5Mu7dCj9a99G+DFBtcAT/HMDChgeDnV4lQ7tLuubPgTv&amp;TOPIC_ID=109724\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125390s010lbl.pdf#page=14</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046433\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer SubQ into the abdomen, thigh, or upper arm once daily at the same time every day; administer any time of day without regard to the timing of meals. Rotate injection sites daily. Doses exceeding 1 mL may be administered as 2 equally divided injections.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147908\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials in the refrigerator at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C); protect from light until preparing for use. Keep vials in the carton when not in use. Do not freeze.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When reconstituted with bacteriostatic water for injection (BWFI), the vial can be used for multiple doses within 3 days when stored in the refrigerator at 36&deg;F to 46&deg;F (2&deg;C to 8&deg;C) and protected from light. When reconstituted with sterile water for injection (SWFI), the vial can be used for a single dose and should be administered immediately. Unused reconstituted solution should be discarded. After reconstitution, the vials should not be frozen (below 0&deg;C). If the reconstituted product is inadvertently frozen, it should be discarded.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046429\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital or acquired generalized lipodystrophy (FDA approved in pediatric patients [age not specified] and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24047795\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, fatigue, headache, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Decreased glucose tolerance (in patients with antibodies to metreleptin), diabetes mellitus (in patients with antibodies to metreleptin), hypoglycemia, increased serum triglycerides (in patients with antibodies to metreleptin), ovarian cyst, weight gain (in patients with antibodies to metreleptin), weight loss</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, nausea, pancreatitis (in patients with a history of pancreatitis)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Proteinuria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, elevated glycosylated hemoglobin (in patients with antibodies to metreleptin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Immunogenicity (anti-metreleptin antibodies)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Severe infection (in patients with antibodies to metreleptin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Erythema at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Otic infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaplastic large cell lymphoma, autoimmune hepatitis (progression), hypersensitivity (including anaphylaxis, skin rash, urticaria), membranoproliferative glomerulonephritis (progression), T-cell lymphoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23877794\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity (eg, anaphylaxis, urticaria, generalized rash) to metreleptin or any component of the formulation; general obesity (not associated with congenital leptin deficiency)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147906\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Antibody development: <b>[US Boxed Warning]: Antimetreleptin antibodies with neutralizing activity have been identified with metreleptin use. Consequences could include inhibition of endogenous leptin action and/or loss of metreleptin efficacy; severe infection and/or worsening of metabolic control have been reported. Test patients who develop severe infections or show signs of loss of metreleptin efficacy for anti-metreleptin antibodies with neutralizing activity. Contact the manufacturer (1-866-216-1526) for neutralizing antibody testing of clinical samples.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Generalized hypersensitivity (eg, urticaria, generalized rash) has been reported; instruct patients to promptly seek medical advice regarding discontinuation of metreleptin if hypersensitivity reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lymphomas: <b>[US Boxed Warning]: T-cell lymphoma has been reported in patients with acquired generalized lipodystrophy (both treated and not treated with metreleptin). Consider the benefits and risks of metreleptin treatment in patients with significant hematologic abnormalities and/or acquired generalized lipodystrophy.</b> A causal relationship has not been established; acquired lipodystrophies are associated with autoimmune disorders, and autoimmune disorders are associated with increased risk of malignancy (including lymphoma).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Autoimmune disorders: Progression of autoimmune hepatitis and membranoproliferative glomerulonephritis associated with massive proteinuria and renal failure have been observed; causal relationship with metreleptin treatment has not been established; acquired lipodystrophies themselves are associated with autoimmune disorders. Consider the benefits/risks of metreleptin treatment in patients with autoimmune disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pancreatitis: In patients with risk factors for pancreatitis (eg, history of pancreatitis, severe hypertriglyceridemia) who require discontinuation of metreleptin, taper the dose over a 1-week period and monitor triglyceride levels; evaluate signs/symptoms of pancreatitis. Consider initiating or adjusting the dose of lipid-lowering medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Injection contains benzyl alcohol when reconstituted with bacteriostatic water for injection (BWFI); large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Safety and effectiveness have not been established for the treatment of partial lipodystrophy or liver disease, including nonalcoholic steatohepatitis. Not indicated for use in patients with HIV-related lipodystrophy or for use in patients with metabolic disease (eg, diabetes mellitus, hypertriglyceridemia) without concurrent evidence of congenital or acquired generalized lipodystrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; REMS program: [US Boxed Warning]: Access is restricted through a REMS program. Prescribers and pharmacies must be certified with the program; information is available at www.myaleptrems.com or 1-855-669-2537.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23906842\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23906839\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=109724&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Metreleptin may decrease the serum concentration of CycloSPORINE (Systemic). Metreleptin may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Estrogen Derivatives (Contraceptive): Metreleptin may decrease the serum concentration of Estrogen Derivatives (Contraceptive). Metreleptin may increase the serum concentration of Estrogen Derivatives (Contraceptive). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Insulins: Metreleptin may enhance the hypoglycemic effect of Insulins.  Management: Insulin dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Progestins (Contraceptive): Metreleptin may decrease the serum concentration of Progestins (Contraceptive). Metreleptin may increase the serum concentration of Progestins (Contraceptive). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Metreleptin may enhance the hypoglycemic effect of Sulfonylureas.  Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline: Metreleptin may decrease the serum concentration of Theophylline. Metreleptin may increase the serum concentration of Theophylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Warfarin: Metreleptin may decrease the serum concentration of Warfarin. Metreleptin may increase the serum concentration of Warfarin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147903\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24147904\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Adverse events were observed in animal reproduction studies. Because metreleptin can restore metabolic and endocrine function, normal menses may be restored in women with previous amenorrhea; fertility may be restored and pregnancies may occur. Reports of use of metreleptin during pregnancy are limited (Chou 2011; Chou 2013; Maguire 2013).</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">Adverse pregnancy outcomes are associated with lipodystrophy in pregnant women, including eclampsia, gestational diabetes, intrauterine growth retardation, intrauterine death, macrosomia, and miscarriage. Based on in vitro data, metreleptin may inhibit uterine contractility during labor. A monitoring program is available for pregnant women exposed to metreleptin during pregnancy. Pregnant women or their health care provider may enroll by calling 1-855-669-2537.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29046434\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Test for antimetreleptin antibodies with neutralizing activity in patients who develop severe infections or show signs of loss of efficacy. Closely monitor blood glucose in patients on concomitant insulin or insulin secretagogue therapy. During tapering in patients at risk for pancreatitis, monitor triglyceride levels.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24151642\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Recombinant human leptin analog that binds to and activates the human leptin receptor (ObR) (which belongs to the class I cytokine family of receptors that signals through the JAK/STAT transduction pathway) to treat complications of leptin deficiency associated with generalized lipodystrophy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24151644\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: 4-5 times plasma volume</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: No apparent systemic metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 3.8-4.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: 4 hours (range: 2-8 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Renal (major route); clearance delayed in the presence of leptin antibodies and may be delayed in renal impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F24942717\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Myalept Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">11.3 mg (1): $5,056.51</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Araujo-Vilar D, S&aacute;nchez-Iglesias S, Guill&iacute;n-Amarelle C, et al. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience. <i>Endocrine</i>. 2015;49(1):139-17<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/25367549/pubmed\" target=\"_blank\" id=\"25367549\">25367549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Beltrand J, Beregszaszi M, Chevenne D, et al. Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy. <i>Pediatrics</i>. 2007;120(2):e291-296.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/17671040/pubmed\" target=\"_blank\" id=\"17671040\">17671040</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chan JL, Lutz K, Cochran E, et al. Clinical effects of long-term metreleptin treatment in patients with lipodystrophy. <i>Endocr Pract</i>. 2011;17(6):922-932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/22068254/pubmed\" target=\"_blank\" id=\"22068254\">22068254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou K, Perry CM. Metreleptin: first global approval. <i>Drugs</i>. 2013;73(9):989-997.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/23740412/pubmed\" target=\"_blank\" id=\"23740412\">23740412</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chou SH, Chamberland JP, Liu X, et al. Leptin is an effective treatment for hypothalamic amenorrhea. <i>Proc Natl Acad Sci U S A</i>. 2011;108(16):6585-6590.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/21464293/pubmed\" target=\"_blank\" id=\"21464293\">21464293</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Diker-Cohen T, Cochran E, Gorden P, Brown RJ. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin. <i>J Clin Endocrinol Metab</i>. 2015;100(5):1802-1810.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/25734254/pubmed\" target=\"_blank\" id=\"25734254\">25734254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Javor ED, Cochran EK, Musso C, Young JR, Depaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy. <i>Diabetes</i>. 2005;54(7):1994-2002.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/15983199/pubmed\" target=\"_blank\" id=\"15983199\">15983199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maguire M, Lungu A, Gorden P, Cochran E, Stratton P. Pregnancy in a woman with congenital generalized lipodystrophy: leptin's vital role in reproduction. <i>Obstet Gynecol</i>. 2012;119(2 pt 2):452-455.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/22270436/pubmed\" target=\"_blank\" id=\"22270436\">22270436</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Myalept (metreleptin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oral EA, Simha V, Ruiz E, et al. Leptin-replacement therapy for lipodystrophy. <i>N Engl J Med</i>. 2002;346(8):570-578.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/metreleptin-pediatric-drug-information/abstract-text/11856796/pubmed\" target=\"_blank\" id=\"11856796\">11856796</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 109724 Version 14.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F24147898\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F24673744\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F29046428\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F29046431\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F24673745\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F24147902\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F24170123\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F29046433\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F24147908\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F29046429\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F24047795\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F23877794\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F24147906\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F23906842\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F23906839\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F24147903\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F24147904\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F29046434\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F24151642\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F24151644\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F24942717\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/109724|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=metreleptin-drug-information\" class=\"drug drug_general\">Metreleptin: Drug information</a></li><li><a href=\"topic.htm?path=metreleptin-patient-drug-information\" class=\"drug drug_patient\">Metreleptin: Patient drug information</a></li></ul></div></div>","javascript":null}